Truveta Data allows researchers to study trends in treatment access, outcomes, and safety in this demographic, which is often underrepresented in clinical trials
Concurrently, telehealth platforms dramatically expanded access to these medications, 1821 with some services explicitly marketing semaglutide for weight loss in non-diabetic populations
For patients using GLP-1 therapy, the goal should not be scale weight alone
The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion
found that semaglutide could reverse the decrease in the levels of tyrosine hydroxylase, alleviate inflammation, and increase autophagy, thus protecting dopaminergic neurons in substantia nigra and striatum (75)
A recent survey from the North American Neuro-Ophthalmology Society (NANOS) recently demonstrated that the median wait time to receive care for new patients, many of whom present with acute concern, is 6 weeks [1]